treatment

EUROSTAD Highlights Use of Systemic Therapies in Adults With Atopic Dermatitis

The results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (AD) (EUROSTAD) were reported in a recent publication in the Journal of Dermatological Treatment.

Researchers aimed to describe the patient characteristics, outcomes, and the median drug survival in a prospective observational study of patients with moderate to severe AD receiving systemic treatment in European countries. The EUROSTAD trial was designed to characterize real-world conditions of patients with AD receiving treatment. Study outcomes included clinical and patient-reported outcomes in addition to systemic therapy, treatment change, and reason for discontinuation over a 12-month period.

The systemic medications taken and reported by 288 patients were cyclosporine (42.7%), dupilumab (35.3%), methotrexate (28.1%), oral corticosteroids (25.4%), azathioprine (6.8%), injectable corticosteroids (6.1%), and mycophenolate (3.4%). The longest duration of treatment was a median of 14.9 months for dupilumab, followed by 7.3 months for methotrexate, 4.8 months for cyclosporine, 3.2 months for injectable corticosteroids, and 1.1 months for oral systemic corticosteroids. Efficacy, patient decision, adverse events, and disease well controlled were reasons for stopping treatment.

“In conclusion, this 12-month interim EUROSTAD study analysis highlights the current trends and duration of use in systemic treatments for moderate-to-severe AD,” wrote the study authors. “Among all systemic treatments for AD, dupilumab was the least likely to be discontinued, while cyclosporine and corticosteroids were primarily limited to episodic flare management, consistent with current treatment guidelines,” they added.

 

—Jessica Garlewicz 

 

Reference:

de Bruin-Weller M, Pink AE, Ferrucci SM, et al. Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). J Dermatolog Treat. 2022;1-6. doi:10.1080/09546634.2022.2038361

Submit Feedback

Name